OR WAIT null SECS
June 17, 2015.
Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the US and Europe, fueling a projected five percent increase in global prescription sales over the next five years according to the EvaluatePharma World Preview 2015, Outlook to 2020 report. The 2015 World Preview states that:
Lisa Urquhart, Editor of EP Vantage, the editorial arm of Evaluate, commented: “Any fears that the pharmaceutical industry might be heading towards a slowdown after the last two years of phenomenal growth can be put to rest for now. However, for the industry to sustain this impressive growth they will have to make compromises around global pricing and market access. As such, pharmaceutical companies need to either accept lower prices for its products, or persuade payers that the therapeutic benefits outweigh the cost of disease.” The EvaluatePharma World Preview 2015, Outlook to 2020 report can be downloaded at